Can't say I disagree with you. I'll be selling some on the day this gets approved, and getting back in a few months before FDA approval (whenever that comes). But I'm not giving this company another 4 years of my life waiting on vitiligo after all this.
Give me a mgmt team that keeps its timelines and provides a decent long-term ROI.
cuv9900 is not a patch - it appears to be some topical formulation. Starting a safety trial for it isn't going to deter the EMA from approving the implant for EPP.
nomura "maa review should complete by start 4q, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$10.86 |
Change
0.090(0.84%) |
Mkt cap ! $544.3M | |||
| Open | High | Low | Value | Volume |
| $10.60 | $10.86 | $10.54 | $732.3K | 68.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1776 | $10.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.95 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |